Low endotoxin anti-rat primary antibodies are purified immunoglobulins that bind specific rat antigens and have been manufactured and quality-controlled to minimize bacterial lipopolysaccharide (LPS) contamination. They are essential for applications in which trace endotoxin would confound biological readouts—most notably in vivo administration, ex vivo cell manipulation, and functional assays using primary immune cells—and they represent a distinct quality tier rather than a different antigen-binding specificity.

Applications

The defining applications of low endotoxin anti-rat primary antibodies are those in which the antibody must interact with living cells or organisms.

In vivo studies. These reagents are used for target neutralization, receptor blockade, and cell depletion in rat disease models. The reduced endotoxin load minimizes inflammatory confounding, which is critical when the endpoint is an immune or inflammatory readout. Representative examples include anti-rat CD8a (clone OX-8) and anti-rat CD71 (clone OX-26) in vivo antibodies, as well as anti-rat TCR γ/δ (clone V65) for the γ/δ T cell subset expressed mainly in epithelial tissues and at sites of infection.

Ex vivo cell manipulation and functional assays. Low endotoxin reagents are used where LPS contamination would confound immune readouts, including crosslinking rat monoclonal antibodies to trigger or block receptor signaling, bridging antibodies onto effector or target cells, and functional assays involving primary immune cells. Anti-rat CD28 (clone JJ319) is documented for costimulation assays at 2–5 µg/mL.

Sensitive immunoassays. The low endotoxin format is also used in ELISA, Western blotting, flow cytometry, immunoprecipitation, and immunohistochemistry when the assay is performed on primary cells or in systems where LPS-driven activation would alter the result.